Literature DB >> 18425916

Chinese herbal medicine for primary dysmenorrhoea.

X Zhu1, M Proctor, A Bensoussan, E Wu, C A Smith.   

Abstract

BACKGROUND: Conventional treatment for primary dysmenorrhoea has a failure rate of 20% to 25% and may be contraindicated or not tolerated by some women. Chinese herbal medicine may be a suitable alternative.
OBJECTIVES: To determine the efficacy and safety of Chinese herbal medicine for primary dysmenorrhoea when compared with placebo, no treatment, and other treatment. SEARCH STRATEGY: The Cochrane Menstrual Disorders and Subfertility Group Trials Register (to 2006), MEDLINE (1950 to January 2007), EMBASE (1980 to January 2007), CINAHL (1982 to January 2007), AMED (1985 to January 2007), CENTRAL (The Cochrane Library issue 4, 2006), China National Knowledge Infrastructure (CNKI, 1990 to January 2007), Traditional Chinese Medicine Database System (TCMDS, 1990 to December 2006), and the Chinese BioMedicine Database (CBM, 1990 to December 2006) were searched. Citation lists of included trials were also reviewed. SELECTION CRITERIA: Any randomised controlled trials involving Chinese herbal medicine versus placebo, no treatment, conventional therapy, heat compression, another type of Chinese herbal medicine, acupuncture or massage. Exclusion criteria were identifiable pelvic pathology and dysmenorrhoea resulting from the use of an intra-uterine contraceptive device. DATA COLLECTION AND ANALYSIS: Quality assessment, data extraction and data translation were performed independently by two review authors. Attempts were made to contact study authors for additional information and data. Data were combined for meta-analysis using either Peto odds ratios or relative risk (RR) for dichotomous data or weighted mean difference for continuous data. A fixed-effect statistical model was used, where suitable. If data were not suitable for meta-analysis, any available data from the trial were extracted and presented as descriptive data. MAIN
RESULTS: Thirty-nine randomised controlled trials involving a total of 3475 women were included in the review. A number of the trials were of small sample size and poor methodological quality. Results for Chinese herbal medicine compared to placebo were unclear as data could not be combined (3 RCTs). Chinese herbal medicine resulted in significant improvements in pain relief (14 RCTs; RR 1.99, 95% CI 1.52 to 2.60), overall symptoms (6 RCTs; RR 2.17, 95% CI 1.73 to 2.73) and use of additional medication (2 RCTs; RR 1.58, 95% CI 1.30 to 1.93) when compared to use of pharmaceutical drugs. Self-designed Chinese herbal formulae resulted in significant improvements in pain relief (18 RCTs; RR 2.06, 95% CI 1.80 to 2.36), overall symptoms (14 RCTs; RR 1.99, 95% CI 1.65 to 2.40) and use of additional medication (5 RCTs; RR 1.58, 95% CI 1.34 to 1.87) after up to three months of follow-up when compared to commonly used Chinese herbal health products. Chinese herbal medicine also resulted in better pain relief than acupuncture (2 RCTs; RR 1.75, 95% CI 1.09 to 2.82) and heat compression (1 RCT; RR 2.08, 95% CI 2.06 to 499.18). AUTHORS'
CONCLUSIONS: The review found promising evidence supporting the use of Chinese herbal medicine for primary dysmenorrhoea; however, results are limited by the poor methodological quality of the included trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18425916     DOI: 10.1002/14651858.CD005288.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  21 in total

1.  Maturation of the adrenal medulla--IV. Effects of morphine.

Authors:  T R Anderson; T A Slotkin
Journal:  Biochem Pharmacol       Date:  1975-08-15       Impact factor: 5.858

2.  National German Guideline (S2k): Guideline for the Diagnosis and Treatment of Endometriosis: Long Version - AWMF Registry No. 015-045.

Authors:  U Ulrich; O Buchweitz; R Greb; J Keckstein; I von Leffern; P Oppelt; S P Renner; M Sillem; W Stummvoll; R-L De Wilde; K-W Schweppe
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-12       Impact factor: 2.915

Review 3.  Evidence from the Cochrane Collaboration for Traditional Chinese Medicine therapies.

Authors:  Eric Manheimer; Susan Wieland; Elizabeth Kimbrough; Ker Cheng; Brian M Berman
Journal:  J Altern Complement Med       Date:  2009-09       Impact factor: 2.579

4.  Interdisciplinary S2k Guidelines for the Diagnosis and Treatment of Endometriosis: Short Version - AWMF Registry No. 015-045, August 2013.

Authors:  U Ulrich; O Buchweitz; R Greb; J Keckstein; I von Leffern; P Oppelt; S P Renner; M Sillem; W Stummvoll; K-W Schweppe
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-09       Impact factor: 2.915

5.  Prevalence and use of complementary health approaches among women with chronic pelvic pain in a prospective cohort study.

Authors:  Maria T Chao; Priscilla D Abercrombie; Sanae Nakagawa; Steven E Gregorich; Lee A Learman; Miriam Kuppermann
Journal:  Pain Med       Date:  2014-10-03       Impact factor: 3.750

Review 6.  Uterotonic plants and their bioactive constituents.

Authors:  Christian W Gruber; Margaret O'Brien
Journal:  Planta Med       Date:  2010-09-15       Impact factor: 3.352

Review 7.  Treating gynaecological disorders with traditional Chinese medicine: a review.

Authors:  Jue Zhou; Fan Qu
Journal:  Afr J Tradit Complement Altern Med       Date:  2009-07-03

Review 8.  Nonsteroidal anti-inflammatory drugs for dysmenorrhoea.

Authors:  Jane Marjoribanks; Reuben Olugbenga Ayeleke; Cindy Farquhar; Michelle Proctor
Journal:  Cochrane Database Syst Rev       Date:  2015-07-30

Review 9.  Dietary supplements for dysmenorrhoea.

Authors:  Porjai Pattanittum; Naowarat Kunyanone; Julie Brown; Ussanee S Sangkomkamhang; Joanne Barnes; Vahid Seyfoddin; Jane Marjoribanks
Journal:  Cochrane Database Syst Rev       Date:  2016-03-22

10.  Use of herbal dietary supplement si-wu-tang and health-related quality of life in postpartum women: a population-based correlational study.

Authors:  Pei-Jen Chang; Ching-Chun Lin; Yi Chun Chen; Chao-Hua Chuang; Yu-Ching Tseng; Wu-Shiun Hsieh; Shio-Jean Lin; Pau-Chung Chen
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-14       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.